Literature DB >> 2137464

Regional cerebral glucose metabolism is normal in young adults with Down syndrome.

M B Schapiro1, C L Grady, A Kumar, P Herscovitch, J V Haxby, A M Moore, B White, R P Friedland, S I Rapoport.   

Abstract

Regional CMRglc (rCMRglc) values were measured with [18F]2-fluoro-2-deoxy-D-glucose (18FDG) and positron emission tomography (PET), using a Scanditronix PC-1024-7B scanner, in 14 healthy, noninstitutionalized subjects with trisomy 21 (Down syndrome; DS) (mean age 30.0 years, range 25-38 years) and in 13 sex-matched, healthy volunteers (mean age 29.5 years, range 22-38 years). In the DS group, mean mental age on the Peabody Picture Vocabulary Test was 7.8 years and dementia was not present. Resting rCMRglc was determined with eyes covered and ears occluded in a quiet, darkened room. Global gray CMRglc equaled 8.76 +/- 0.76 mg/100 g/min (mean +/- SD) in the DS group as compared with 8.74 +/- 1.19 mg/100 g/min in the control group (p greater than 0.05). Gray matter regional measurements also did not differ between groups. The ratio of rCMRglc to global CMRglc, calculated to reduce the variance associated with absolute rCMRglc, and right/left ratios did not show any consistent differences. These results show that healthy young DS adults do not have alterations in regional or global brain glucose metabolism, as measured with 18FDG and PET, prior to an age at which the neuropathological changes in Alzheimer disease are reported to occur.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137464     DOI: 10.1038/jcbfm.1990.35

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  7 in total

1.  Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation.

Authors:  Mei Qin; Julia Kang; Carolyn Beebe Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Regionally selective decreases in cerebral glucose metabolism in a mouse model of phenylketonuria.

Authors:  M Qin; C Beebe Smith
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

3.  Alzheimer's Disease in Down Syndrome.

Authors:  Elizabeth Head; David Powell; Brian T Gold; Frederick A Schmitt
Journal:  Eur J Neurodegener Dis       Date:  2012-12

4.  Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid.

Authors:  H U Shetty; M B Schapiro; H W Holloway; S I Rapoport
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

5.  Dissociation of Down syndrome and Alzheimer's disease effects with imaging.

Authors:  Dawn C Matthews; Ana S Lukic; Randolph D Andrews; Boris Marendic; James Brewer; Robert A Rissman; Lisa Mosconi; Stephen C Strother; Miles N Wernick; William C Mobley; Seth Ness; Mark E Schmidt; Michael S Rafii
Journal:  Alzheimers Dement (N Y)       Date:  2016-06

Review 6.  Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis.

Authors:  Elizabeth Head; David K Powell; Frederick A Schmitt
Journal:  Front Aging Neurosci       Date:  2018-06-21       Impact factor: 5.750

7.  Measuring cerebral perfusion with [11C]-PiB R1 in Down syndrome: associations with amyloid burden and longitudinal cognitive decline.

Authors:  Elijah Mak; Monika Grigorova; Jessica Beresford-Webb; Maura Malpetti; Madeline Walpert; Stephanie Brown; Elizabeth Jones; Isabel Clare; Young T Hong; Tim D Fryer; Jonathan P Coles; Franklin I Aigbirhio; David K Menon; Peter J Nestor; Anthony J Holland; Shahid H Zaman
Journal:  Brain Commun       Date:  2020-11-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.